Patents by Inventor Ilan Vaknin

Ilan Vaknin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF
    Publication number: 20240139318
    Abstract: Anti-PVRIG and anti-TIGIT antibodies are provided.
    Type: Application
    Filed: August 21, 2023
    Publication date: May 2, 2024
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Maya Kotturi, Hsin-Yuan Cheng, Kyle Hansen, David Nisim Giladi, Einav Safyon, Eran Ophir, Leonard Presta, Richard Theolis, Radhika Desai, Patrick Wall
  • ANTI-PVRIG ANTIBODIES AND METHODS OF USE
    Publication number: 20240101669
    Abstract: The present invention is directed to anti-PVRIG antibodies and methods of using same.
    Type: Application
    Filed: August 11, 2023
    Publication date: March 28, 2024
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Leonard Presta, Richard Theolis
  • ANTI-PVRIG ANTIBODIES FORMULATIONS AND USES THEREOF
    Publication number: 20240082397
    Abstract: The present invention is directed to anti-PVRIG antibodies and stable liquid pharmaceutical formulations thereof. The present invention is directed to monotherapy and combination treatments with anti-PVRIG antibodies and anti-PD-1 antibodies, in particular nivolumab, using stable liquid pharmaceutical formulations thereof.
    Type: Application
    Filed: January 28, 2022
    Publication date: March 14, 2024
    Inventors: Mark WHITE, Inbal BARBIRO, Ilan VAKNIN, Assaf WOOL, Zurit LEVINE, Henry Adeboye ADEWOYE, MD, Michael BUCKLEY, Jun LU, John HUNTER, Anat COHEN-DAYAG, Gad S. COJOCARU, Eran OPHIR, Zoya ALTEBER
  • ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF
    Publication number: 20240075137
    Abstract: Anti-PVRIG and anti-TIGIT antibodies are provided.
    Type: Application
    Filed: May 23, 2023
    Publication date: March 7, 2024
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Maya Kotturi, Hsin-Yuan Cheng, Kyle Hansen, David Nisim Giladi, Einav Safyon, Eran Ophir, Leonard Presta, Richard Theolis, Radhika Desai, Patrick Wall
  • COMBINATION THERAPY WITH ANTI-PVRIG ANTIBODIES FORMULATIONS AND ANTI-PD-1 ANTIBODIES
    Publication number: 20240076373
    Abstract: The present invention is directed to anti-PVRIG antibodies and stable liquid pharmaceutical formulations thereof. The present invention is directed to monotherapy and combination treatments with anti-PVRIG antibodies and anti-PD-1 antibodies, in particular nivolumab, using stable liquid pharmaceutical formulations thereof. The present invention also provides biomarkers for use in determining populations for treatment with anti-PVRIG antibodies and such biomarkers include, for example PVRIG and/or PVRL2 expression.
    Type: Application
    Filed: January 28, 2022
    Publication date: March 7, 2024
    Inventors: Inbal BARBIRO, Ilan VAKNIN, Assaf WOOL, Zurit LEVINE, Paul A. BASCIANO, Brian D. LAMON, Henry Adeboye ADEWOYE, John HUNTER, Anat COHEN-DAYAG, Gad S. COJOCARU, Eran OPHIR, Zoya ALTEBER
  • PVRIG POLYPEPTIDES AND METHODS OF TREATMENT
    Publication number: 20240025973
    Abstract: The present invention is directed to PVRIG polypeptides and their uses.
    Type: Application
    Filed: September 1, 2023
    Publication date: January 25, 2024
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Amir Toporik, Yossef Kliger, Ofer Levy, Arthur Machlenkin, Sergey Nemzer, Yair Benita, Amit Novik
  • COMBINATION THERAPY WITH ANTI-PVRIG ANTIBODIES FORMULATIONS, ANTI-TIGIT ANTIBODIES, AND ANTI-PD-1 ANTIBODIES
    Publication number: 20230365680
    Abstract: The present invention is directed to combination treatments with anti-PVRIG antibodies, anti-TIGIT antibodies, and anti-PD-1 antibodies, in particular nivolumab, using stable liquid pharmaceutical formulations thereof.
    Type: Application
    Filed: September 30, 2021
    Publication date: November 16, 2023
    Inventors: Adeboye Henry ADEWOYE, MD, Inbal BARBIRO, Ilan VAKNIN, Eran OPHIR, Pierre FERRE
  • Anti-PVRIG antibodies and methods of use
    Patent number: 11795220
    Abstract: The present invention is directed to anti-PVRIG antibodies and methods of using same.
    Type: Grant
    Filed: June 17, 2020
    Date of Patent: October 24, 2023
    Assignee: COMPUGEN LTD.
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Leonard Presta, Richard Theolis
  • PVRIG polypeptides and methods of treatment
    Patent number: 11795209
    Abstract: The present invention is directed to PVRIG polypeptides and their uses.
    Type: Grant
    Filed: January 28, 2020
    Date of Patent: October 24, 2023
    Assignee: COMPUGEN LTD.
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Amir Toporik, Yossef Kliger, Ofer Levy, Arthur Machlenkin, Sergey Nemzer, Yair Benita, Amit Novik
  • Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
    Patent number: 11701424
    Abstract: Anti-PVRIG and anti-TIGIT antibodies are provided.
    Type: Grant
    Filed: June 17, 2020
    Date of Patent: July 18, 2023
    Assignee: COMPUGEN LTD.
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Maya Kotturi, Hsin-Yuan Cheng, Kyle Hansen, David Nisim Giladi, Einav Safyon, Eran Ophir, Leonard Presta, Richard Theolis, Radhika Desai, Patrick Wall
  • ILDR2 antagonists and combinations thereof
    Patent number: 11655297
    Abstract: The present invention relates to a novel pharmaceutical combination comprising an ILDR2 antagonist according to any of the aforementioned claims, plus one or more other therapeutically active compounds, and to novel specific ILDR2 antagonists.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: May 23, 2023
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Compugen LTD.
    Inventors: Lars Röse, Uwe Gritzan, Julia Hütter, Spencer Liang, Andrew Pow, John Hunter, Ofer Levy, Ilan Vaknin
  • Anti-PVRIG antibodies and methods of use
    Patent number: 11623955
    Abstract: The present invention is directed to anti-PVRIG antibodies and methods of using same.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: April 11, 2023
    Assignee: COMPUGEN LTD.
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Leonard Presta, Richard Theolis
  • COMBINATIONS OF ANTI-ILDR2 ANTIBODIES AND PD-1 ANTAGONISTS
    Publication number: 20220169736
    Abstract: The present invention relates to an anti-ILDR2 antibody, a fragment or derivative thereof, a modified antibody format, or an antibody mimetic for use in combination with a PD-1 antagonist in the treatment of cancer. Other aspects of the present invention relate to a combination comprising an anti-ILDR2 antibody and a PD-1 antagonist and the use of such combination as a medicament, as well as methods of treatment or prophylaxis of a cancer in a subject, comprising administering to said subject a therapeutically effective amount of the antibodies as described herein. Further, the present invention relates to a kit comprising anti-ILDR2 antibodies and PD-1 antagonists and optionally one or more further pharmaceutical agents.
    Type: Application
    Filed: April 6, 2020
    Publication date: June 2, 2022
    Applicants: Bayer Aktiengesellschaft, Compugen LTD.
    Inventors: Lars RÖSE, Uwe GRITZAN, Spencer LIANG, Andrew POW, John HUNTER, Ofer LEVY, Ilan VAKNIN
  • Anti-PVRIG antibodies and methods of use
    Patent number: 11220542
    Abstract: The present invention is directed to anti-PVRIG antibodies and methods of using same.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: January 11, 2022
    Assignee: Compugen Ltd.
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Leonard Presta, Richard Theolis
  • ANTI-PVRIG ANTIBODIES AND METHODS OF USE
    Publication number: 20210188974
    Abstract: The present invention is directed to anti-PVRIG antibodies and methods of using same.
    Type: Application
    Filed: June 17, 2020
    Publication date: June 24, 2021
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Leonard Presta, Richard Theolis
  • Kit for diagnosis, prognosis, and monitoring the immune status, of patients with chronic inflammatory diseases
    Patent number: 10914743
    Abstract: Provided are methods and kits, e.g.; for testing the immune status of patients with chronic inflammatory diseases by measuring the TCR zeta chain (CD247) expression levels, and in particular a method and a kit for testing the selective downregulation of TCR zeta chain expression in T cells, NK cells, or NKT cells. Zeta chain expression is measured using antibodies directed against the intracellular zeta chain region, and these levels are compared with the expression levels of other T cell receptor subunits and NK cell markers. Provided are methods for determining diabetes complications in a diabetic patient. Further provided are kits for diagnosis, prognosis, and monitoring of same.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: February 9, 2021
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Michal Baniyash, Ilan Vaknin
  • ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF
    Publication number: 20210000952
    Abstract: Anti-PVRIG and anti-TIGIT antibodies are provided.
    Type: Application
    Filed: June 17, 2020
    Publication date: January 7, 2021
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Maya Kotturi, Hsin-Yuan Cheng, Kyle Hansen, David Nisim Giladi, Einav Safyon, Eran Ophir, Leonard Presta, Richard Theolis, Radhika Desai, Patrick Wall
  • PVRIG POLYPEPTIDES AND METHODS OF TREATMENT
    Publication number: 20200385445
    Abstract: The present invention is directed to PVRIG polypeptides and their uses.
    Type: Application
    Filed: January 28, 2020
    Publication date: December 10, 2020
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Amir Toporik, Yossef Kliger, Ofer Levy, Arthur Machlenkin, Sergey Nemzer, Yair Benita, Amit Novik
  • ILDR2 ANTAGONISTS AND COMBINATIONS THEREOF
    Publication number: 20200369769
    Abstract: The present invention relates to a novel pharmaceutical combination comprising an ILDR2 antagonist according to any of the aforementioned claims, plus one or more other therapeutically active compounds, and to novel specific ILDR2 antagonists.
    Type: Application
    Filed: November 28, 2018
    Publication date: November 26, 2020
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Compugen LTD.
    Inventors: Lars RÖSE, Uwe GRITZAN, Julia HÜTTER, Spencer LIANG, Andrew POW, John HUNTER, Ofer LEVY, Ilan VAKNIN
  • ANTI-VSIG10 ANTIBODIES AND METHODS OF USE
    Publication number: 20200270343
    Abstract: A monoclonal or polyclonal antibody or an antigen binding fragment thereof comprising an antigen binding site that binds specifically to an isolated polypeptide comprising amino acids of the soluble ectodomain of a sequence selected from the group consisting of SEQ ID NOs:3 and 5, or a fragment, thereof, or an epitope thereof; for use in treatment of cancer, wherein immune cells in the microenvironment of said cancer express said isolated polypeptide.
    Type: Application
    Filed: June 8, 2018
    Publication date: August 27, 2020
    Inventors: Ofer LEVY, Gad S. COJOCARU, Liat DASSA, Tal FRIDMAN-KFIR, Ilan VAKNIN, Einav GANGULI, Finav GANGULI, Drew PARDOLL